Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis
170 Followers
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.67 - $18.07
Previous Close$16.6
Volume1.78M
Average Volume (3M)1.07M
Market Cap
$1.45B
Enterprise Value$1.05B
Total Cash (Recent Filing)$405.54M
Total Debt (Recent Filing)$514.00K
Price to Earnings (P/E)-7.0
Beta-0.51
Next Earnings
Aug 06, 2024EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding87,384,856
10 Day Avg. Volume2,694,188
30 Day Avg. Volume1,067,741
Standard Deviation0.35
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue286.53
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.24
Forecast
1Y Price Target
$35.78Price Target Upside109.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Unveils Updated Corporate Presentation
PremiumCompany Announcements
Day One Biopharmaceuticals Achieves FDA Approval and Rare VoucherBulls Say, Bears Say
Bulls Say
Financial OutlookAnalyst reiterates an Overweight rating on DAWN shares, signaling confidence in the long-term potential of Ojemda.
Product LaunchThe Ojemda launch has begun with physicians showing enthusiasm for its clinical profile, addressing an unmet need in the market.
Regulatory MilestoneFDA approval of Ojemda for pediatric low-grade glioma with BRAF alterations represents a significant regulatory achievement and market opportunity.
Bears Say
Drug Launch And AdoptionConcerns arise from the possibility of sluggish early adoption of Ojemda as patients who are in remission or well-managed with current treatments may resist switching to the new medication.
Drug PricingA price tag of approximately $400,000 annually for Ojemda is significantly higher than competitors, potentially limiting demand due to its premium cost.
Financial StabilityThe company may face financial challenges, with a potential need to raise additional capital if the launch of Ojemda does not meet the expected timelines and revenue targets.
---
Ownership Overview
56.78% Insiders
20.12% Mutual Funds
22.82% Other Institutional Investors
0.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.67 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 90 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on May 06, 2024. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.057.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.72.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,384,860 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 114M.
---
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.78 (109.48% Upside)
$35.78 (109.48% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 518.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.34%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
7.73%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Stock 12 Month Forecast
Average Price Target
$35.78
▲(109.48% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Helius Medical Technologies
―
Mersana Therapeutics
―
Guardion Health Sciences
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+6.75%
reiterated a buy rating 2 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +6.75% per trade.
---